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Killing of HIV-infected cells by CD8+ T-cells imposes strong selection pressure on the virus 
toward escape. The HLA class I molecules that are successful in mediating some degree 
of control over the virus are those that tend to present epitopes in conserved regions 
of the proteome, such as in p24 Gag, in which escape also comes at a significant cost 
to viral replicative capacity (VRC). In some instances, compensatory mutations can fully 
correct for the fitness cost of such an escape variant; in others, correction is only partial. 
The consequences of these events within the HIV-infected host, and at the population 
level following transmission of escape variants, are discussed. The accumulation of 
escape mutants in populations over the course of the epidemic already shows instances 
of protective HLA molecules losing their impact, and in certain cases, a modest decline 
in HIV virulence in association with population-level increase in mutants that reduce VRC.
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iNTRODUCTiON
The ability of HIV to evade the immune response is one of the major challenges standing in the way 
of the development of a successful HIV vaccine. Although the drive to improve immune control via 
T-cell vaccines has been diminished following the Step and Phambili trials involving the MRKAd5 
HIV-1 vaccine (1–4), success of a T-cell vaccine using a CMV vector in the SIV-macaque model 
(5–8) and the increasing recognition that CD8+ T-cells are likely to play a critical role in HIV eradica-
tion (9, 10) underlines the continuing importance of antiviral T-cell activity in HIV vaccine and 
Cure approaches. Understanding the impact of CD8+ T-cell escape both within the host and at the 
population level therefore remains of critical relevance to the field.
Almost 25 years have elapsed since the initial discovery that HIV variation could result in viral 
escape from the CD8+ T-cell response (11). This early work focused on the HLA-B*27-restricted 
response to an immunodominant epitope in the Gag protein KRWIILGLNK (“KK10”: Gag 263–272). 
Much has been learned about HIV adaptation to HLA class I-restricted CD8+ T-cell responses and 
its potential consequences from this single response. HLA-B*27 provides an especially clear example 
because, first of all, HLA-B*27 is strongly associated with slow progression to HIV disease (12–16). 
Second, the peptide-binding motif is so clean: only one amino acid is acceptable at position-2 (P2) 
in the epitope (17–20). Third, immunodominance is very strong (13), so, although a simplification, 
much of the story can be read by focusing on KK10 alone. Fourth, by chance, very few other CD8+ 
T-cell responses target epitopes in this region. Therefore, certainly in Caucasian populations infected 
with B clade virus, any mutations within KK10 can safely be assumed to have been the result of selec-
tion pressure driven by this HLA-B*27 response. Fifth, escape almost invariably involves substitution 
TABLe 1 | Selected key epitopes with HLA restriction, and associated Hiv-1 escape and compensatory mutations.
Protein epitope HLA restriction Sequencea escape mutation Compensatory mutation
Gag TL9 B*07:02/42:01/81:01 TPQDLNTML Q182T, Q182E/G/S, T186S E177D, V191I
Gag GL9 B*07:02 GPSHKARVL S357G
Gag RM9 B*07:02/42:01 RPGGKKHYM H28Q/S/R, M30R/K R20S
Gag KK10 B*27:05 KRWIILGLNK R264K/G/T/Q, L268M/I S165N, S173A
Gag QK10 B*27:05 QRGNFRNQRK R380K, F383Y
Pol KY9 B*27:05 KRKGGIGGY R902K, K903R, G908E
Nef WF9 B*27:05 WRFDSRLAF R104K, R108X
Vpr VL9 B*27:05 VRHFPRIWL R32K, R36G
Vif KK11 B*27:05 KRKPPLPSVTK R159G
Gag NY10 B*35:01 NPPIPVGDIY D260E
Pol TI8 B*51:01 TAFTIPSi I135T/R
Gag ISW9 B*57:02/57:03 AiSPRTLNAW A146P, I147L/M
Gag KF11 B*57:01/57:03 KAFSPEVIPMF A163G/S S165K/N
Gag TW10 B*57:03/58:01 TSTLQEQIAW T242N H219Q, I223V, M228L
Gag QW9 B*57:02/57:03/58:01 QATQDVKNW A309S, T310S
Nef KF9 B*57:02/57:03/58:01 KAAFDLSFF A83G
Env QL11 B*58:02 QTRVLAERYL None
aBold residue indicates escape mutation selected.
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of Arg at P2, which effectively abrogates binding and immuno-
genicity of the epitope for any HLA-B*27-positive recipient of the 
variant. Finally, this immunodominant KK10 response illustrates 
an important feature of most, if not all the epitopes that appear 
to mediate HLA-associated control of HIV infection, namely 
that escape mutation within the epitope significantly reduces 
viral replicative capacity (VRC). This last point underlines that 
fact that viral fitness is a critical factor in determining timing and 
impact of escape mutations.
wiTHiN HOST HLA ADAPTATiON: 
LeSSONS TAUGHT BY HLA-B*27
The HLA-B*27-restricted KK10 response was the first HIV-
specific epitope described (21), a fact that is related to its immuno-
dominance in HIV-infected individuals who express HLA-B*27 
(13, 22). HLA-B*27 is reasonably prevalent in Caucasian popula-
tions (phenotype frequency ~8%) (20) and individuals expressing 
HLA-B*27 progress relatively slowly to disease (12–14, 23, 24); 
therefore, longitudinal studies of this response were feasible. The 
KK10 escape mutations within KK10 appeared to be selected 
late – after a decade or more of infection – and were associated 
with progression to AIDS (13). The dominant observed escape 
mutation, R264K, arises at the anchor position-2 (P2) in the 
epitope that is believed to require Arginine for adequate bind-
ing to HLA-B*27 (17–20). These data suggested the possibility 
that KK10 might be an important immune response mediating 
the protection against rapid disease progression linked with 
HLA-B*27.
The main features of this “B27 story” have remained broadly 
unaltered over the past two decades, although it has become 
more complex. First, KK10 is by no means the only HIV-specific 
response, nor is it necessarily the first CD8+ T-cell response to 
emerge in the very early phase of infection in subjects expressing 
HLA-B*27. The initial response appears to be against the Vpr 
epitope “VL9” (Vpr 31–39: VRHFPRIWL) and escape in VL9, 
again via an Arg → Lys substitution at the P2 anchor, predates 
the R264K escape mutation within KK10. Although KK10 is usu-
ally the dominant response in chronic infection, more sensitive 
and more comprehensive assays have revealed between 15 and 
20 additional HIV-specific HLA-B*27-restricted epitopes (22; 
Leitman, Personal communication). This includes a Pol epitope 
“KY9” (Pol 901–909, KRKGGIGGY) which in some subjects can 
be the immunodominant response and within which selection 
of escape mutations (Arg → Lys at P2 and/or Gly → Glu at P8) 
can predate escape within KK10 (22; Leitman, Personal commu-
nication) (Table 1). Thus, the HLA-B*27-restricted CD8+ T-cell 
response is much more broadly based than initially realized.
Second, although selection of the R264K is associated with 
progression to AIDS, the mutation L268X (where X represents 
Met or Ile at P6 in the KK10 epitope) occurs prior to R264K, 
and this is associated with reduced immune control. Typically, 
progression to a CD4 count of <200 cell/mm3 or AIDS appears 
to require the mutation at Arg-264 which abrogates binding of 
KK10 to HLA-B*27, and therefore would abolish the CD8+ T-cell 
response altogether, whereas L268X merely reduces recognition. 
A subset of the KK10-specific CD8+ T-cells that recognize the 
wild-type epitope have a high functional avidity and are the most 
potent inhibitors of viral replication (25–30); so loss of this subset 
of CD8+ T-cells as a result of selection of the L268X mutant loos-
ens the hold of the KK10 response over the virus. As described 
further below, this now appears to prepare the conditions for 
R264K to be selected.
Third, the selection of R264K many years after infection 
prompts the question of why this occurs so late. Part of the expla-
nation is that the R264K mutant itself inflicts a substantial cost 
on VRC such that a compensatory mutation – S173A – needs 
to be selected at the same time as the escape variant (23, 31). In 
fact, alternative escape mutants to R264K are also selected, prin-
cipally R264G and R264T, that do not impair VRC as much as 
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R264K (32), but impair VRC substantially more than the R264K/
S173A combination. Thus, there is a balance between the benefit 
the virus accrues from evading the KK10 response and the cost 
of the escape mutant. Selection of R264K invariably follows that 
of L268X, which, as described above, weakens the efficacy of the 
KK10 response; in the setting of L268X, therefore, the additional 
benefit of R264T and T264G may not be of sufficient value to the 
virus to be worth the cost. On the other hand, in the setting of 
a highly potent KK10 response, prior to the selection of L268X, 
R264T, or R264G might result in the complete evasion of the 
KK10 response, at a cost to VRC that was of overall benefit to 
the virus. For these reasons, with rare exceptions, R264K escape 
is only seen in combination with S173A, following selection 
of L268X (31), whereas R264T or R264G are typically selected 
without L268X having been selected previously (23) (Table 1).
It should be added here that late escape does not always imply 
a strong CTL response and a fitness cost resulting from the escape 
mutation. Late escape could also arise in the setting where either 
there are constraints against escape mutation or the CTL response 
is weak.
The fourth complication is the influence of the particular viral 
context within which these escape mutants are selected. This is 
most readily observed when considering the escape pathways 
available to HIV from different clades of virus. The options for 
KK10 escape in B clade infection have been described above. 
In C clade virus infections, which predominate in Africa and 
therefore in the global epidemic, the situation differs. In par-
ticular, instead of Ser at Gag-173, the C clade consensus residue 
at this position is Thr. This clade-specific difference at Gag-173 
might be expected to influence the cost of R264K escape and the 
necessity for a compensatory mutation at Gag-173 as is observed 
in B clade infection. In fact, what we see in KK10 escape in C 
clade HLA-B*27-positive individuals is the selection of R264K 
without prior escape at L268, and the compensatory mutation is 
typically S165N (Brener, Personal communication). In addition, 
changes in residues within the cyclophilin A-binding loop, a 
region within the capsid protein spanning Pro-217 to Pro-225 
(PVHAGPIAP), may provide an alternative route by which com-
pensation for the fitness cost of R264K can be achieved in C clade 
infection. However, the R264K/S173A escape and compensatory 
pathway employed predictably in B clade infection is not adopted 
in C clade. These examples illustrate the point that the escape 
pathways adopted in each infected individual are shaped by the 
particular autologous viral sequences in operation as well as by 
the immune response.
The final complication to add to the original “B27 story” is 
the question of what distinguishes the HLA-B*27-positive HIV-
infected individuals who are “elite controllers” [antiretroviral 
therapy (ART)-naïve subjects whose viral loads are undetectable 
(<50 copies/ml plasma)] from those who do not exhibit the same 
degree of viremic control. In some cases, as described above, if 
KK10 escape mutants have been selected, this would explain 
failure of the KK10 response to suppress viral replication. In other 
subjects, in whom KK10 escape mutants have not been selected, 
qualitative differences in the ability of KK10-specific CD8+ T-cells 
to recognize low concentrations of the KK10 variants may help 
to explain elite control in HLA-B*27-positive individuals (33). 
Although Arg at P2 is believed to be a requirement of any HLA-
B*27-binding peptide, it is possible that an Arg →  Lys mutant 
might merely reduce presentation of the peptide, as opposed 
to abolishing it altogether, which might be sufficient for some 
KK10-specific cells of very high functional avidity to maintain 
recognition of, and kill, even those virus-infected cells expressing 
the KK10 variant.
wiTHiN HOST HLA ADAPTATiON: 
LeSSONS LeARNT FROM NON-HLA-B*27 
ALLeLeS
HLA-B*57 and HLA-B*58:01
HLA-B*57 is highly enriched in HIV elite controllers [reviewed 
in Ref. (34)] and is the HLA class I allele with the strongest impact 
on viral load setpoint and disease progression (12, 15, 16, 35–40). 
Within the sub-Saharan African population, where the HIV 
epidemic is concentrated, HLA-B*57:03 is the most prevalent 
HLA-B*57 subtype, expressed in ~4–5% of individuals. It differs 
by one amino acid from HLA-B*57:02 (Leu-156 in B*57:03, Arg-
156 in HLA-B*57:02), the less common HLA-B*57 subtype found 
in sub-Saharan African populations. The HLA-B*57 alleles are 
also closely related to HLA-B*58:01, all being protective against 
HIV disease progression and sharing presentation of many of the 
same epitopes. The hierarchy of protection is, in ascending order, 
HLA-B*58:01, HLA-B*57:02, and HLA-B*57:03 (41), and this 
order is associated with the number of p24 Gag-specific CD8+ 
T-cell responses that drive selection pressure on the virus. In the 
case of HLA-B*57:03, selection of mutations arises in three p24 
Gag-specific epitopes, in a predictable sequence (42–44). HLA-
B*57:02- and HLA-B*58:01-restricted p24 Gag responses drive 
selection pressure in only two instances.
The TW10 epitope (TSTQEQIAW, Gag 240–249), is presented 
by all three closely related HLA-B*57:02/57:03/58:01 class I 
molecules, and escape mutants at T242X are selected in 70–90% 
of individuals expressing these alleles. This mutation shares 
many features with the R264K mutation within the HLA-B*27-
restricted KK10 epitope described above. The most common 
mutant, T242N, effectively abrogates recognition by CD8+ T-cells 
(42, 45, 46). At the same time, T242N also reduces VRC (42, 43, 
45). Unlike R264K, reversion of T242N following transmission 
to a recipient who does not express the relevant HLA class I mol-
ecule, does arise commonly (42), because compensatory mutants 
appear to be less efficient at correcting the fitness cost than S173A 
is for R264K (32). However, if compensatory mutations, such as 
H219Q, I223X, and M228X, are selected in combination with 
T242N, the speed of reversion post-transmission may be consid-
erably diminished (47) (Table 1).
The p24 Gag epitope that is uniquely presented by HLA-
B*57:03 among this group of related HLA-B*57/58:01 alleles is 
KF11 (KAFSPEVIPMF, Gag 162–172) (35). This is the immuno-
dominant HLA-B*57:03-restricted epitope in chronic infection, 
targeted by >75% of infected individuals expressing HLA-B*57:03. 
The sequence of events observed for escape within KF11 has close 
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similarities with those described above for KK10 escape through 
R264K. The initial escape mutation within KF11 is A163X, typi-
cally A163G, located at position-2 in the epitope, which reduces 
but does not abrogate recognition of the epitope by KF11-specific 
CD8+ T-cells. This mutant carries a cost for the virus, in that A163G 
reduces VRC (48, 49). The fitness cost of A163G is substantially, 
although not fully, restored by the compensatory mutation S165N 
that emerges subsequent to A163G (43, 48, 49). Furthermore, the 
combination of A163G and S165N results in the complete loss 
of recognition of the epitope by CD8+ T-cells. Thus, as with the 
fully compensated HLA-B*27-R264K escape, the virus ultimately 
achieves almost the perfect solution, that is, complete escape from 
T-cell recognition with minimal loss of VRC (Table 1).
In summary, the HLA-B*57/58:01 alleles present a clear pic-
ture, consistent with that described in relation to the HLA-B*27-
restricted Gag response, suggesting a mechanism for HLA-linked 
control of HIV through the dominant targeting of Gag, with 
strong selection pressure for escape variants that reduce VRC 
and that therefore require the virus also to select compensatory 
mutants for adequate replication. However, although individual 
compensatory mutants, such as S165N, may help to compensate 
for the fitness cost of the escape mutant, in this case A163G, an 
accumulation of costly escape mutants may severely attenuate the 
virus (43). This is what appears to result in the face of the three 
HLA-B*57:03-restricted, p24 Gag-specific CD8+ T-cell responses 
that drive selection pressure on HIV. Thus, although the virus 
is constantly generating variants that may diminish the cost of 
escape mutants, in many cases, the compensation will be incom-
plete, and/or take some time, and therefore a broad Gag-specific 
CD8+ T-cell response is likely to be highly effective in long-term 
suppression of viremia. This may also explain the observation 
that HLA-B*57-positive elite controllers have often selected rare 
B*57 mutations that substantially reduce VRC with no apparent 
accompanying compensatory variant (50). By contrast, escape 
mutations outside Gag, such as in Env, may have minimal impact 
on VRC (51), and these responses are typically not associated 
with control of viremia (52).
Additional insight into the effect of MHC class I alleles 
involved in control HIV infection comes from an elegant study 
by Wroblewski et al. that over a period of 50 years followed three 
communities of chimpanzees (P. t. schweinfurthii) infected with 
SIVcpz (53) in the Gombe National Park, Tanzania (54). DNA 
and RNA were extracted from fecal dumps to study longitudi-
nal changes of MHC and SIVcpz viral loads over time. Three 
chimpanzee MHC alleles (Patr-B*06:03/B*22:03/B*22:05) were 
enriched in the SIVcpz-infected groups. Of particular interest, in 
the case of HLA-B*57 and control of HIV, is the Patr-B*06:03 
allele because it phylogenetically clusters with HLA-B*57:01, 
shares a similar B-pocket binding structure and is associated 
with lower SIVcpz viral load. SIVcpz sequencing showed varia-
tion in Gag-242, T242S, suggesting selection pressure from Patr-
B*06:03-restricted SIVcpz specific CD8+ T-cells and similar to 
that demonstrated for the HLA-B*57/58:01-associated T242N 
mutation in HIV. The study from Wroblewski et al. also suggests 
that SIVcpz infection results in particular Patr-B alleles becoming 
enriched in the chimpanzee population.
Other African HLA-B Alleles Contributing 
to Control
The other HLA allele strongly associated with protection against 
disease progression in African subjects infected with HIV is 
HLA-B*81:01 (16, 38, 55, 56). HLA-B*81:01 restricts a dominant 
TL9 p24 Gag response (TPQDLNTML, Gag 180–188) (57) that 
drives, in particular, the selection of T186S (44, 58, 59) that sub-
stantially reduces VRC. The compensatory mutations at Gag-190 
only partially restore the fitness cost from these intra-epitope 
mutations (60).
This single p24 Gag epitope, TL9, has taught us several 
additional aspects of CD8+ T-cell immunity. This is the most 
targeted HIV-specific epitope in sub-Saharan Africa, being 
presented by several highly prevalent HLA alleles, including 
HLA-B*07:02/B*39:10/B*42:01/B*81:01 and HLA-C*08:02. The 
immunodominance pattern for each HLA allele is influenced 
by TCR bias, such that the TCR gene rearrangements neces-
sary for the immunodominant TL9-specific responses arise 
more readily than those necessary for non-dominantly targeted 
epitopes restricted by the same allele (61). A further point this 
epitope illustrates is that although ultiple HLA-B alleles present 
TL9, the frequency and patterns of the mutations they select are 
often distinct, and these have a different impact on VRC. Several 
explanations have been proposed to explain the stronger selection 
imposed via HLA-B*81:01 on TL9 compared to HLA-B*42:01. 
First, TL9-specific CD8+ T-cells restricted by HLA-B*81:01 and 
HLA-B*42:01 have different TCR clonotype usage. Second dif-
ferent TCR affinities may result in different cross-recognition 
properties of TL9 variants (62, 63). Third, the HLA-specific 
conformation of the TL9 peptide differs greatly in 3-dimentional 
space (59). These factors may explain a wider phenomenon of 
distinct escape pathways adopted by the virus in the face of CD8+ 
T-cell responses to the identical epitope but restricted by different, 
albeit closely related HLA class I molecules. At the population 
level, this can lead to discordant HLA-associated impact on VRC 
and on disease outcomes (44).
HLA-B*42:01 and the closely related HLA-B*42:02 make a 
particularly informative case study, as they differ by only a single 
amino acid (64), occur almost exclusively on the same haplotype 
together with HLA-A*30:01 and HLA-C*17:01, and, as Bw6 
alleles, they have no interaction with KIR ligands (65). Thus, dis-
ease associations can be more easily attributed to the CD8+ T-cell 
responses these alleles, respectively, generate. The impact of the 
single residue change is striking, with HLA-B*42:01 significantly 
superior to HLA-B*42:02 as a protective allele (55, 58). Perhaps 
unsurprisingly, the ultimate mechanism reflects the patterns 
observed for HLA-B*27 and HLA-B*57, in that HLA-B*42:02 
has a narrow Gag response and does not effectively present key 
Gag epitopes, such as p17 Gag RM9 and p24 Gag TL9, that are 
strongly targeted by B*42:01 (64). This is consistent with previous 
studies demonstrating differences in rates of AIDS progression 
associated with single amino acid differences between HLA-
B*35 subtypes, such as B*35:01 compared with B*35:02/03 (66). 
Again these differences in disease outcome are linked to higher 
frequency of Gag epitope targeting by HLA-B*35:01 compared 
with HLA-B*35:02/3 (67).
FiGURe 1 | HLA-B*27 footprints in B clade Hiv show a predictable 
pattern of escape mutation among six different epitopes. The 12 
HLA-B*27-associated escape variants within six HLA-B*27-restricted 
epitopes are shown in red. Shaded are the common escape positions at P2 
in the epitope in each case, in all cases from Arg → Lys or Gly. Data from 
Carlson et al. (44, 75).
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Disease-Susceptible HLA Alleles
Insight to the mechanisms underlying HIV control also comes 
from studies of HLA alleles associated with rapid progression. In 
contrast to protective alleles such as HLA-B*27/57/58:01/81:01, 
the CD8+ T-cell response restricted by disease-susceptible HLA 
fail to constrain viral replication and hence do not impose selec-
tion pressure on the virus (68). HLA-B*42:02, as described above, 
is an example of a disease-susceptible allele. The second example 
is HLA-B*58:02 that is associated with rapid disease progression 
(38, 55, 69), despite being closely related to a protective allele, 
HLA-B*5801. These two HLA molecules differ by only three 
amino acids, but, as with B*42:01 and B*42:02, the consequence 
is two very distinct immonodominance patterns. The dominant 
HLA-B*58:01-restricted response is the p24 Gag epitope TW10, 
escape from which reduces VRC (described above). However, the 
dominant HLA-B*58:02-restricted response is directed toward an 
epitope in Env, targeting of which is associated with high viral 
loads and no selection pressure (69). These observations are 
consistent with a recent study that identifies 21 epitopes with 
disease progression, of which only one is located in p24 Gag and 
the majority (15 epitopes) arise within Env or Pol (70).
The question of what happens when an individual expresses 
both a protective and disease-susceptible allele has been addressed 
by Leslie et al. (55) (JV 2010) who showed that the effect of alleles 
on immune control is additive. Viral loads are intermediate. CTL 
responses are not dominated by Gag, as in subjects only express-
ing protective alleles, but include responses in Env and in the 
accessory/regulatory proteins (52).
HLA-C Contribution to Hiv Control
Although HLA-C is expressed at lower levels than either HLA-A 
or HLA-B on the cell surface (71), a single nucleotide polymor-
phism (SNP), arising 35 kilobases upstream of the HLA-C locus, 
was shown to be protective against HIV disease progression (15, 
16). Subsequently, this polymorphism was associated with higher 
HLA-C expression levels on the surface of T-cells (40) independ-
ent of HLA-A and HLA-B linkage disequilibrium (72). The 
mechanism is linked to variation within the 3′ untranslated region 
of HLA-C that regulates the binding of the microRNA Has-miR-
148a (expressed on chromosome 7) and thereby also the levels 
of HLA-C expression (73). Variation in the gene encoding the 
microRNA Hsa-miR-148a directly affects HLA-C allele expres-
sion, such that high expression of miR-148a down-regulates those 
HLA-C alleles containing the corresponding microRNA-binding 
site (74). These studies suggest a new mechanism in which dif-
ferential expression of HLA-C alleles may play important roles in 
control of viremia due to greater HLA-C restricted CD8+ T-cell 
activity and selection pressure (38, 52, 72). Thus, differences in 
relative HLA expression levels (71) may directly impact on CD8+ 
T-cell activity and contribution to HIV control.
POPULATiON-LeveL HLA ADAPTATiON
HLA Footprints
As mentioned above, escape mutations within HLA-B*27-
restricted epitopes in addition to the immunodominant Gag 
epitope KK10 are selected in HIV-infected individuals expressing 
this allele. These can be identified in cohort studies of HLA-typed 
subjects as HLA-B*27 “footprints” on the HIV sequence via 
demonstration of statistical associations between the presence of 
a variant, such as R264X (where X is either K, G, T, or Q), and 
expression of HLA-B*27. Carlson et al. (75) have constructed an 
escape map of the HIV B clade proteome, from the study of 1888 
ART-naïve, chronically infected individuals. A similar escape 
map has been constructed for Gag, Pol, and Nef C clade sequences 
(76). From these studies, 12 HLA-B*27-associated mutations can 
be mapped onto six HLA-B*27-restricted CD8+ T-cell epitopes 
(Figure  1). A clear pattern can be identified from observation 
of these epitopes and the escape mutants that arise therein. In 
accordance with the requirement for Arg at P2 in HLA-B*27-
binding peptides, all these epitopes carry Arg at P2, and in all 6 
epitopes, substitution of Arg at P2 is the common (although not 
exclusive) escape route for the virus.
The realization that the viral sequencing of large cohorts of 
HLA-typed individuals could reveal effectively all the escape 
mutants selected at any meaningful level was first described by 
Moore et al. (77). These types of analyses are particularly valu-
able in identifying responses that are functional, as only these 
will impose sufficient selection pressure on the virus for escape 
mutants to be selected. The identification of HLA footprints can 
also help to uncover previously unknown epitopes that might 
make critical contributions to the acute response but are often 
undetectable in chronic infection, following early escape in acute 
infection.
It is also important to note that the HLA footprints can be 
“indirect” (76): that is, they are dependent on the presence of 
another HLA footprint: an example here would be the compensa-
tory mutant S173A, whose selection in HLA-B*27-positive indi-
viduals is dependent on coselection of the R264K escape mutant. 
Additionally, there may be HLA footprints that are not necessar-
ily linked with viral escape from the CD8+ T-cell response, but 
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may be selected because they affect KIR binding to peptide–MHC 
complexes and thereby influence NK-mediated killing (78).
The final point concerning the identification of HLA footprints 
on the viral proteome is the information that these studies provide 
about which responses are important for immune control. In the 
study of the C clade epidemic in South Africa, it emerged that the 
number of Gag footprints per HLA molecule was strongly linked to 
the HLA-associated viral setpoint (68). So, highly protective HLA 
molecules, such as HLA-B*57/58:01/81:01, select a large number 
of Gag escape mutants, whereas disease-susceptible alleles, such 
as HLA-B*18:01/58:02, select none. This relationship did not 
apply to the number of Pol or Nef HLA footprints. Furthermore, 
the inverse correlation between viral load and number of HLA 
footprints was the strongest when limiting the analysis only to 
reverting mutants, that is, mutants that tend to revert back to the 
original sequence following transmission to an HLA-mismatched 
recipient (discussed further below). Following on from studies 
showing strong correlations between the breadth of the Gag CD8+ 
T-cell response and viral suppression, and inverse correlations 
for Nef- and Env-specific CD8+ T-cell responses (52), these data 
provide an entirely independent piece of evidence supporting the 
central role of Gag-specific CD8+ T-cell responses in the control 
of HIV infection.
Transmission, Persistence, or Reversion 
of CTL escape variants
The first question that arises is whether the CD8+ T-cell escape 
mutants can be transmitted. A number of mother–child trans-
mission studies (79–81) and adult horizontal transmission 
studies (43, 76, 80, 82–85) have shown that this is indeed the 
case. Interestingly, a recent analysis of adult transmission (76) 
showed that where a mixture of wild-type and variant sequences 
is present in the donor, the wild-type virus is preferentially trans-
mitted. This, in itself, is further supporting evidence that some of 
these escape mutants have a real impact on viral fitness. Having 
said this, it is clear that even escape mutants that reduce VRC 
significantly can be transmitted, and often are (43, 47, 76, 80–85).
The next question is whether transmitted variants would per-
sist in HLA-mismatched recipients or revert back to the original 
sequence in the absence of the CD8+ T-cell response that drove 
their selection. In theory, one might anticipate that variants having 
effectively no impact on VRC would persist, while those reduc-
ing VRC would revert. In the case of the HLA-B*27-associated 
R264K mutant, the fitness cost of this escape mutation is almost 
entirely corrected by the simultaneous selection of the compensa-
tory S173A variant (31). Thus, transmission of the R264K/S173A 
combination to an HLA-B*27-negative recipient does not appear 
to result in reversion back to wild type (32). Escape mutants that 
significantly reduce VRC, and for which compensatory mutants 
only partially recover the fitness cost – examples described above 
include the HLA-B*57/58:01-associated mutant T242N, or the 
HLA-B*81:01-associated T186S (43, 48, 49, 51, 60) – do revert the 
following transmission to HLA-mismatched recipients. However, 
reversion does not necessarily happen within a few months of 
transmission in spite of the peak viral loads of ~107  copies/ml 
plasma that occur during acute infection; rather, reversion may 
not occur for some years (42, 47, 80). This suggests that in some 
cases, the fitness costs of these mutants may be mitigated by an 
unpredictable combination and variety of compensatory mutants, 
the precise nature of which may vary from patient to patient 
and therefore that may be difficult to pinpoint. Alternatively, if 
viral loads are high and immune responses are weak, selection 
pressure may not be sufficient to discern between viruses with 
modestly differing VRC. Put another way, the selection pressure 
for reversion may be relatively weak in such settings, whereas the 
original pressure for the selection of the escape mutant must have 
exceeded the cost to VRC.
There is some evidence in support of this latter hypothesis 
from studies of infected children. In contrast to adult infection, in 
which a vigorous immune response brings viral load to a setpoint 
within 6  weeks of infection, viral loads in ART-naïve children 
remain at >1 × 106 copies/ml for the first year or more and decline 
slowly to a quasi-setpoint at around 5 years of age (86, 87). This 
gradual decline in viremia in childhood infection coincides with 
the development of a more effective CD8+ T-cell response with 
increasing age (88), and it appears that reversion of mutants, such 
as T242N, in HLA-B*57/58:01-negative children is delayed until 
the maturing antiviral immune response is sufficiently potent to 
impose significant traction on the virus (80).
impact of Transmission of escape 
variants: HLA-Matched Recipients
We establish above the fact that HLA-B*27-driven escape 
mutants typically include variants that abrogate HLA binding of 
the variant peptide that can be transmitted, and that, in the case 
of epitopes such as KK10, these variants do not normally revert 
post-transmission. One would predict, therefore, that the HLA-
B*27-positive recipients of these variants would fail to generate 
any of the responses that would be expected to drive selection 
pressure on the virus (Figure 2). The impact of escape-variant 
transmission to HLA-B*27-positive adults has not been reported 
to date. However, in a small study of six HLA-B*27-positive, 
HIV-infected children, a KK10 response was not detectable in the 
children who were recipients of R264X variants from the mother, 
and progression was relatively rapid. By contrast, when wild-type 
KK10-encoding virus was transmitted, a strong KK10 response 
was evident. Indeed, one such child was a very rare pediatric “elite 
controller,” with viremia remaining below the limit of detection 
(<50 c/ml) for almost a decade. Progression finally occurred fol-
lowing the selection of the R264T mutant and loss of the KK10 
response (89).
The outcome of escape variant transmission would differ 
from the scenario described for KK10 above if the escape mutant 
did have a significant fitness cost. An example here is the HLA-
B*57/58:01-associated escape mutant T242N, described above, 
commonly driven by the TW10 response restricted by these 
alleles (Figure 2). Like R264K, T242N is a variant that signifi-
cantly reduces VRC; however, S173A almost perfectly repairs the 
damage caused by R264K, the H219Q/I223V/M228L combina-
tion of compensatory mutations for T242N incompletely restores 
VRC (32). The fitness cost of T242N does vary quite consider-
ably between individuals (90), depending upon the overall Gag 
FiGURe 2 | impact of transmission of escape mutant to HLA-matched and to HLA-mismatched recipient. Two examples are shown to illustrate differing 
impact of transmission of escape variants. Left: transmission of escape mutation (R264K) where the virus is fully compensated by the compensatory mutation 
S173A. Right: transmission of escape mutation (T242N), where the compensatory mutant H219Q does not fully restore viral fitness (H219Q).
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sequence context in which it sits, and the timing of reversion of 
T242N back to wild type can range from months to years fol-
lowing transmission to an HLA-B*57/58:01-negative recipient 
(47). Therefore, the consequence for HLA-B*57/58:01-positive 
recipients of T242N escape variants is mixed: on the one hand, the 
virus has lower VRC and this is therefore a benefit; on the other 
hand, the recipient is deprived of the TW10-specific response. 
A further complication here is that the T242N variant does not 
prevent binding of TW10 to HLA-B*57/58:01, and a T242N-
specific response can be generated (91). However, the efficacy of 
variant-specific responses, such as these, is not well established as 
the variants are often less immunogenic than the wild-type (92). 
The precise cost/benefit balance to the newly infected recipient 
might hinge on the degree of compensation achieved by the virus 
to recover the fitness cost of the escape mutant and the potency 
of the CD8+ T-cell response that is nullified by transmission of 
the escape variant.
impact of Transmission of escape 
variants: HLA-Mismatched Recipients
In the situation where these two respective mutants are transmit-
ted to HLA-mismatched recipients, the effects would be nil in the 
case of the fully compensated R264K variant and of benefit to the 
recipient in the case of the T242N variant that still carries a fit-
ness cost (Figure 2). This process, then, of transmission of escape 
mutants would only be detrimental in the minority of cases where 
the HLA of the recipient happened to match that of the donor. 
This result is precisely that described in studies of Zambian adult 
transmission pairs (82, 84) showing that newly infected individu-
als fared better in terms of CD4 count and viral setpoint if the 
virus they were infected with carried escape mutants associated 
with protective HLA-B alleles such as HLA-B*57/58:01/81:01, 
unless the new recipients themselves carried those same protec-
tive alleles as the donor. In other cases, all things being equal, 
transmission of virus with low VRC results in higher CD4 counts 
and lower viral loads in the recipient.
Accumulation of escape variants at the 
Population Level
The observation that escape mutants with effectively no fitness 
cost attached could be transmitted and persist long term in 
HLA-mismatched recipients would suggest that over time, the 
frequency of these escape variants would increase and eventually 
become the dominant form. An indication that this process might 
indeed be occurring arose from the statistical data describing 
associations between certain HIV amino acid polymorphisms 
and expression of particular HLA class I molecules, as described 
above (75). The majority of these associations are between the 
HLA molecule and the minor variant  –  for example, R264X 
(where X is K/G/T/Q) is found in ~10–20% of HLA-B*27-positive 
individuals and in 5–10% of HLA-B*27-negative subjects (47). 
However, a small number of these HLA associations with HIV 
amino acid polymorphisms show a negative association between 
the relevant HLA molecule and the minor variant, and thus the 
HLA association is with the consensus sequence. One example 
is the HLA-B*27 association with an Arg →  Lys substitution 
at Nef-184 (Figure 1). In fact, the consensus sequence has Lys 
at Nef-184. One possible explanation for such a negative HLA 
association with the consensus residue would be that this escape 
mutant has accumulated over time to replace the original “wild-
type” residue. Such epitopes have been termed “negatopes” (93), 
both for the reason that they are epitopes containing a residue 
negatively associated with the restricting HLA molecule and 
because a peptide synthesized according to consensus sequence 
FiGURe 3 | variable speed of variant accumulation. (A) Frequency of HLA-B*35:01-driven D260E variant in a C clade-infected population in which 
HLA-B*35:01 is at low prevalence (phenotypic frequency 4%) compared to a B clade-infected population in which HLA-B*35:01 is at high prevalence (15%).  
(B) Frequency of HLA-B*07:02-driven S357G variant in two comparable Durban cohorts, enrolled in 2002–2005 and 2012–2013. These examples shown in (A,B) 
illustrate escape mutants selected early in the course of infection by a high proportion of subjects expressing the relevant HLA allele, which confer little fitness cost 
on the virus. Therefore, the variant accumulates rapidly in the population. (C) Frequency of HLA-B*57/58:01 A83G variant in two cohorts. The third example of rapid 
accumulation of an escape variant selected early in the course of infection, conferring little fitness cost that accumulates rapidly in the population. (D) Frequency of 
HLA-B*81:01-driven variant T186X. This example illustrates a variant conferring a high fitness cost on the virus, but for which compensatory mutations have only 
very modest effects. Therefore, the T186X variant accumulates very slowly in the population. Data from Kawashima et al. (47), Leslie et al. (93), and Payne et al. (96).
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would carry the escape mutant, and therefore even if a CD8+ T-cell 
response existed, it would almost by definition not be detected. 
The first example was the Nef epitope KAAFDLSFF (Nef residues 
82–90), which is restricted by the closely related HLA molecules 
HLA-B*57 and HLA-B*58:01. The escape mutation is the A → G 
substitution at P2 in the epitope, which substantially reduced 
binding of the variant to HLA-B*57/58:01. In C clade infection, 
the A83G variant is in fact present in >50% of sequences overall. 
Thus, peptides synthesized based on the consensus would be test-
ing recognition of the escape mutant KGAFDLSFF that does not 
bind efficiently to HLA-B*57/58:01, and therefore no response 
would be detected even when a strong response to the wild-type 
KAAFDLSFF was present.
Other factors than the simple accumulation of escape mutants 
over time might contribute to the presence of an escape mutant at 
high frequencies in the population include, in particular, founder 
effect. For this reason, it is necessary for sequences to be “phylo-
genetically corrected” (94) in order to exclude founder effect and 
verify identified HLA associations. An example here would be the 
presence of a handful of C clade sequences from infected Africans 
among a large cohort of mostly B-clade-infected Caucasians. 
Without phylogenetic correction, the analysis would generate 
artifactual HLA associations between HLA alleles prevalent in 
Africans (such as HLA-C*17:01) and polymorphisms specific to 
C clade virus, when no biological link exists. The persistence of 
HLA associations following phylogenetic correction supports the 
notion that HLA, if not the only driving force, is at least contribut-
ing to the accumulation of escape mutants in the population. An 
example here may be the HLA-B*35:01 escape mutant D260E 
within the NY10 epitope (NPPIPVGDIY, Gag 254–262; Figure 3). 
In C clade infection, while 72% of HLA-B*35:01-positive individu-
als carry the escape mutant D260E, Gag-260-D is present in 70% 
of sequences and is therefore the consensus. However, in B clade 
infection, 96% of HLA-B*35:01-positive individuals carry D260E, 
Gag-260-D is present in only 12% of sequences, and Gag-260-E 
is therefore the consensus. Since this D260E mutant appears to 
carry no fitness cost (68), it is likely that HLA-B*35:01-NY10-
specific CD8+ T-cell activity is contributing to the accumulation 
of D260E in B and C clade virus populations (95).
The second line of evidence suggesting that CD8+ T-cell 
escape mutants may be accumulating at the population level over 
the course of the epidemic derives from the observation, among 
nine ethnically diverse cohorts of HIV-infected individuals, of 
a strong correlation between the frequency of escape mutants 
and the prevalence of the relevant HLA molecule in each study 
cohort (47). In Japan, for example, where HLA-B*51 is expressed 
in 20–25% of the population, the HLA-B*51-associated escape 
mutant Pol-I135X is present in two-thirds of HLA-B*51-
negative population. I135X is selected in acute infection in 
>95% of HIV-infected, HLA-B*51-positive individuals, and 
the I135X variants, with one rare exception, have no impact 
on viral fitness. Hence, the conditions for rapid accumulation 
of this variant at the population level are met (97) (Figure 3). 
In Caucasian populations where HLA-B*51 prevalence is 
~10%, the frequency of I135X is ~30% in HLA-B*51-negative 
individuals; and in African populations where the HLA-B*51 
phenotypic frequency is low (1–4%), the frequency of the I135X 
variant is also correspondingly low (~15%). Surprisingly, these 
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studies additionally showed evidence of accumulation of escape 
mutants known to carry a fitness cost on the virus, although as 
expected these appeared to accumulate at slower rates than the 
mutants with no fitness cost attached.
The third study, comparing the frequency of escape mutants at 
the population level at the same location in Durban, South Africa, 
at two time points 10 years apart (2002–2005 and 2012–2013), 
showed a significantly increased frequency of CD8+ T-cell escape 
mutants, further supporting the notion that these escape mutants 
are increasing at the population level over time (96). A similar 
study of the North American epidemic (98) also showed an 
increase in the frequency of escape mutants over time, although 
the relatively modest twofold increase in frequency over a 20-year 
period may reflect a less dramatic HIV epidemic than that 
experienced in sub-Saharan Africa. In addition, the ethnically 
homogeneous Zulu cohorts in Durban, relative to the ethnically 
heterogeneous cohorts in North America, might generate a more 
focused selection pressure and therefore a speedier accumulation 
of mutants in the African population.
Thus, several lines of evidence point to an accumulation of 
escape mutants over time in different cohorts, although rate of 
accumulation might vary according to the population structure, 
the scale of the epidemic, and the nature of the particular escape 
mutant (Figure 3).
Population-Level Accumulation of escape 
Mutants and Loss of Protective HLA 
impact
One might predict, from the data presented above, that escape 
mutants would accumulate over the course of the HIV epidemic, 
albeit at differing rates, and that this would have two potential 
consequences. First, if the HLA associations with slow disease 
progression, such as have been described for HLA-B*27, hinge to 
any extent on particular epitopes, the loss of those epitopes might 
be likely to affect the HLA association with disease outcome. 
Second, if the escape mutants that accumulate at the population 
level carry a fitness cost compared to the original “wild-type” 
virus, this would tend to bring the average replicative capacity of 
the circulating viruses in the population down. Evidence for these 
two possibilities will be discussed below.
The clearest evidence that HLA associations with HIV disease 
outcome are influenced by the availability of certain CTL epitopes 
comes from the SIV-macaque model of HIV infection. The MHC 
molecule Mamu-B*08 in SIV-infected Indian rhesus macaques 
is similar in several respects to HLA-B*27 in HIV-infected 
humans. First, it is associated with successful suppression of 
viremia and with slow progression in SIV infection (99). Second, 
the Mamu-B*08 peptide-binding motif is so similar to HLA-B*27 
that in some cases, the same peptides can bind both Mamu-B*08 
and HLA-B*27; in fact, the SIV-specific Mamu-B*08-restricted 
CD8+ T-cell epitopes include the exact homologs of the HIV-
specific HLA-B*27-restricted epitopes (100). Finally, the domi-
nant Mamu-B*08-restricted CD8+ T-cell epitope is located in a 
highly conserved region of the proteome, escape from which is 
therefore limited by fitness constraints. In the SIV model, the 
question could then be addressed of whether control of SIV 
infection would be lost if viruses carrying escape mutants in all 
the critical Mamu-B*08 epitopes were engineered into the infect-
ing strain of virus. This experiment was performed (101) and the 
result was that control of SIV was indeed compromised by loss 
of these epitopes. Furthermore, failure to control this virus was 
in spite of the reduced VRC incurred as a consequence of all the 
additional mutants. Although the experiment was not done, it is 
possible that this “escaped” virus might have been well contained 
in Mamu-B*08-negative animals, owing to the lower VRC.
In HIV infection, examples of the impact of transmission 
of CTL escape mutants to HLA-matched individuals initially 
were mostly anecdotal. The negation of the protective effect of 
HLA-B*27 in children whose mothers transmit the KK10 escape 
variants has already been described above (79). Larger studies 
of mother–child pairs support these initial findings (80). In 
adults, studies of epidemiologically linked Zambian transmis-
sion pairs also indicate that disease progression is more rapid 
following transmission of CTL escape variants to HLA-matched 
recipients than following transmission of the wild-type virus (43, 
82; Carlson, Personal communication). Thus, the evidence does 
suggest that immune control is reduced and HLA associations 
with slow progression would be disrupted by the accumulation 
of escape mutations over the course of the epidemic.
The second line of evidence supporting the data from transmis-
sion pairs is that emerging from studies of clade-specific differ-
ences in HLA associations with particular HIV disease outcomes. 
An example has been mentioned of the difference between B and 
C clade HIV with respect to the residue at Gag-260: in B clade, 
this is Glu in 88% of cases, whereas in C clade, this residue is Asp 
in 70%. The Gag epitope NPPIPVGDIY (“NY10”; Gag 254–262) 
is only immunogenic when Asp is present at Gag-260, and hence 
the great majority of B clade-infected individuals who are HLA-
B*35:01-positive cannot make a response to NY10. However, in C 
clade infection, the majority if HLA-B*35:01-positive individuals 
can make a response to NY10. Since this NY10 response is asso-
ciated with a 1log10 reduction in viral load (95), it is likely that 
this contributes to the differential clade-specific HLA-B*35:01 
association with HIV disease outcome, that is, with rapid progres-
sion in B clade infection and no association with rapid progression 
in C clade infection. Similar data are published with respect to 
the HLA-B*07:02-restricted p24 Gag-specific epitope, which is 
immunogenic in C clade infection but “escaped” and non-immu-
nogenic in B clade infection (102). In parallel, the association of 
HLA-B*07:02 with rapid progression in B clade infection is not 
observed in C clade infection. Therefore, these data support the 
notion that infection with a virus that is preadapted to the HLA 
type of the recipient will typically have two results. First, infection 
will result in worse outcome. Second, the prevailing HLA associa-
tions with protection against disease progression will be disrupted.
The data that HLA associations with HIV disease outcome 
could already be altering over time are, as one might expect, 
somewhat limited after the relatively short timescales over which 
the HIV epidemic has been operating. However, there is evidence 
that in the 1980s in Japan, early in the epidemic, HLA-B*51 was 
associated with slow progression in HIV infection (12, 14, 47), 
whereas 25 years later, it no longer affords any protective effect 
(47). This loss of protection mediated through HLA-B*51 over 
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a 25-year period in Japan is associated with the apparent rise 
in frequency of the I135X mutation abrogating binding of the 
dominant TAFTIPSI (RT 128–135) epitope described above. 
Consistent with this picture are the data indicating that non-
progression in subjects expressing HLA-B*51 may hinge on the 
lack of escape in the TAFTIPSI epitope (103).
More recently, Payne et al. (96) studied the impact of HIV on 
HLA adaptation in Botswana, one of the countries most severely 
affected by the epidemic, with high seroprevalence taking off in 
the 1980s and rates of adult infection that approached 30% by 
2000. Even today, adult seroprevalence in Botswana remains at 
23%. Although South Africa is the country with the highest abso-
lute number of HIV infections, exceeding >6 m people currently,1 
the duration of the epidemic and the magnitude in terms of adult 
seroprevalence is substantially less than that in Botswana (WHO 
Report 20132). As expected, the degree to which HIV at the popu-
lation level is adapted to the HLA class I molecules expressed in 
the infected individuals in Botswana was substantially higher 
than that in South Africa. Of note, this increased population-
level adaptation of HLA also applied to the related protective 
HLA alleles HLA-B*57 and HLA-B*58:01, although not to the 
protective HLA-B*81:01. This finding prompted the question of 
whether the protection against disease progression that is typi-
cally mediated by HLA-B*57/58:01 is diminished in Botswana 
compared to South Africa. Strikingly, there was no significant 
protection against disease progression, as indicated by viral load, 
afforded by HLA-B*57/58:01 in Botswana. However, in the case 
of HLA-B*81:01, this allele remained protective in Botswana as 
in South Africa.
This is a striking result because HLA-B*57/58:01 has been 
universally associated with the successful suppression of viremia 
in all the previous studies where sufficient subject numbers have 
been sampled (12, 15, 16, 35–40). The number of subjects studied 
in Botswana was relatively high (n > 400), of whom 90 expressed 
HLA-B*57/58:01. As described above, there is evidence also 
from comparable cohorts in Durban recruited, respectively, in 
2002–2005 and in 2012–2013, that CD8+ T-cell escape mutants 
are accumulating, and one would predict therefore that loss of 
HLA-B*57/58:01 protection against disease progression would 
eventually be demonstrated also in South Africa.
It might initially appear surprising that HIV would be able 
to adapt to certain HLA alleles, such as HLA-B*57/58:01, and 
not others, such as HLA-B*81. However, as described above (see 
Figure 3), it is well documented that certain escape variants are 
selected at very high frequency, early in the course of infection, 
and incur little fitness cost to the virus, and hence would accu-
mulate rapidly, whereas others would accumulate substantially 
more slowly. The HLA-B*81:01-driven escape mutant T186X 
within the dominant Gag epitope TL9 (TPQDLNTML, Gag 
180–188) may be such an example (Figure 3), being present in 
only 25–30% of chronically infected subjects expressing HLA-
B*81:01, and carrying a high fitness cost, without clear com-
pensatory mutants being identified to date (60; Tsai, Personal 
1www.avert.org 
2www.who.int/hiv
communication). So, accumulation of this latter escape mutant 
would be slow, and HLA-B*81:01 may remain a long-term pro-
tective HLA allele in HIV infection as a result.
Population-Level Accumulation of escape 
Mutants and impact on Hiv virulence
Markers of Virulence
The population-level adaptation of HIV to a high proportion of 
all the HIV-specific CD8+ T-cell responses generated against the 
virus, including most effective responses that are restricted by 
HLA-B*57/58:01, prompts the question of what impact do these 
events have on virulence of the epidemic. Virulence refers to the 
ability of a microorganism to cause disease (104). Both viral setpoint 
and CD4 count have been used as proxy measures of virulence, 
since the former predicts rate of progression (105) and the latter 
indicates risk of opportunistic infections (106); indeed, a CD4 
count of <200 cells/mm3 is one definition of AIDS. However, it is 
worth noting that these measures are not synonymous with disease 
progression (107). Indeed, it has become increasingly apparent 
that immune activation is a better marker than viral load of disease 
outcome (108). The most obvious example of this is natural SIV 
infection in African non-human primates, such as the sooty man-
gabey and the African green monkey, in which non-pathogenic 
infection operates in the setting of persistent, high viremia and 
low immune activation (109, 110). Non-progressive pediatric 
HIV infection is an example in humans of the same disconnection 
between viral load and disease outcome, normal CD4 T-cell count 
and function, and low immune activation in the setting of per-
sistent high viremia (Adland, Personal  communication). In adult 
HIV infection, immune activation levels predict disease outcome 
better than viral load (108, 111), and CD4 decline to AIDS can be 
observed in elite controllers (whose viral load is undetectable) as 
a result of the strong correlation between absolute CD4 count and 
immune activation (112).
The underlying mechanism by which immune activation 
is maintained at low levels in the setting of high viremia in the 
sooty mangabey and African green monkey appears to be related 
to strong immunoregulatory activity that follows a robust innate 
immune response to SIV in acute infection (110, 113). It is likely 
that host-specific variation in immune activation following HIV 
infection may, in part, explain differential disease outcome in 
HIV infection, although the clearest host genetic impact on rate 
of progression arises from differences in HLA class I molecules 
expressed (114). However, an additional possibility has recently 
been proposed that VRC of the transmitted virus has an impact 
not only on viral setpoint and CD4 count in the recipient (82, 
84) but also more directly on the level of immune activation 
(115). This relationship between VRC of the founder virus and 
early immune activation in the recipient is independent of viral 
load. In addition, as described also in natural SIV infection (116), 
low immune activation in this study was associated with small 
viral reservoirs in naïve and central memory CD4+ T-cells. This 
helps to explain why donor and recipient viral load in transmis-
sion pairs are strongly correlated (117). Therefore, together these 
studies would indicate that VRC may be a stronger predictor of 
virulence than viral load.
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Changing Virulence in the HIV Epidemic – HLA 
Effects
The accumulation of escape mutants, including those reducing 
the replicative capacity of HIV, would suggest the possibility that 
population-level VRC would decline over time (118). The study of 
Payne et al. (96), referred to previously, showed that the substan-
tially higher level of population-level adaptation of HIV observed 
in Botswana compared to South Africa was indeed associated 
with a significantly lower median VRC. As indicated above, VRC 
may be a more direct indicator than the other measurements used 
as a proxy for virulence, namely viral load and CD4 count (115), 
although correlations between VRC and viral load, and/or inverse 
correlations between VRC and CD4 count are described in all 
published studies to date (50, 58, 60, 96, 119–123), including that 
of Payne et al. (96). These data in Botswana suggested that time 
to AIDS in the absence of ART would be extended on average by 
~2.5 years (124) as a result of the viral adaptation observed.
Changing Virulence in the HIV Epidemic – Non-HLA 
Effects
A further question here is whether the lowered VRC in Botswana 
was entirely due to the differential population-level HLA adapta-
tion or whether other factors may have contributed. It seems 
likely that more widespread use of ART, as has occurred in 
Botswana compared to South Africa, would result in lowering of 
population-level VRC. In the absence of ART, the fittest viruses 
are those associated with high viral load and low CD4 count, and 
therefore these are the viruses most likely to be transmitted. In a 
population in whom ART is systematically given to infected sub-
jects with high viral loads and low CD4 counts, the transmission 
rates overall will be reduced, but the viruses transmitted will tend 
to arise from donors who have relatively high CD4 counts and 
therefore relatively low fitness viruses. Mathematical modeling 
of the impact of ART in virulence also appears to support this 
hypothesis (96).
Several other studies have been undertaken that have exam-
ined the question of whether HIV virulence is changing over the 
course of the epidemic, and, if so, in what direction. Herbeck et al. 
(104) published a review of 32 European/North American studies 
on the B clade epidemic, 12 of which indicated that there was no 
change, nine indicated an increase, and 11 a decrease in virulence. 
Subsequent to this review, further studies have suggested a decrease 
in virulence in the HIV epidemic in Japan, as determined by chance 
population-level VRC (122), and the study of the mainly European 
CASCADE cohort [Concerted Action on SeroConversion to AIDS 
and Death in Europe (125)] indicated increasing virulence from 
the early 1980s to 2002, followed by a plateau or slight decline 
thereafter in CD4 counts and viral load, respectively.
These studies undertaking estimates of changing virulence 
face several challenges, including population heterogeneity, the 
discrepancies between different viral load testing platforms, 
accurate definition of seroconversion date, and taking account 
of the impact of widely diverse ART initiation strategies and 
guidelines. However, the CASCADE study adjusted for possible 
confounders using several approaches, and it is useful to consider 
other possible reasons why the findings of these various studies 
might be so diametrically opposite.
One major potential factor is clearly the very different type 
of epidemic operating in the European and North America 
versus the sub-Saharan Africa: the sub-Saharan epidemic is 
mainly comprised of women infected with C clade virus via sex 
with men, whereas the majority of study subjects in European/
North American studies are of B clade-infected men who have 
sex with men (MSM). These differences alone will bring a 
number of other factors into the equation, such as the transmis-
sion of other viral infections, such as CMV, HSV2, hepatitis 
B, and hepatitis C, all of which have a detrimental impact on 
the ability of the immune response to control HIV infection 
(126). In these instances, measurement of VRC might indeed 
provide a closer estimate of virulence. In the case of CMV, in 
sub-Saharan Africa, virtually all individuals are infected by the 
age of 12 months, whereas in Europe and North America, only 
50% of adults are CMV seropositive. The impact of comorbidity 
is difficult to evaluate; however, since poverty, malnutrition, and 
preexisting high prevalence of diseases, such as TB and hepatitis 
B, in sub-Saharan Africa would tend to decrease mucosal bar-
riers to infection, and potentially enable lower fitness viruses to 
be transmitted that would not be transmitted in the setting of a 
healthy mucosal barrier.
The impact of wide availability of antiretroviral drugs for 
the past 20 years for infected individuals in Europe and North 
America, and not to the same extent in sub-Saharan Africa, is 
likely to increase the proportion of transmissions that occur in 
acute or early infection, and therefore involving the fittest and 
most virulent viruses. The estimates of the percentage of trans-
missions that occur during acute infection in the donor range 
widely between studies, from 1 to 50%, with a consensus figure 
of ~25% (127–134). If the proportion of transmissions occurring 
during acute infection is higher in the MSM epidemic, as appears 
likely, especially in the European/North American epidemic 
where later infection is blocked by a very efficient treatment pro-
gram, this might tend to favor increasing virulence. Furthermore, 
in relation to the rate of accumulating CTL escape mutants, early 
transmission would likely preempt the serial passaging of virus 
from one individual to another before the action of the cellular 
immune response on the virus, also diminishing the HLA impact 
on virulence described above.
CONCLUSiON
HLA has had a dramatic impact in a short period of time in shap-
ing evolution of HIV as it has adapted to evade the most effective 
CD8+ T-cell responses generated against it. In Southern Africa, 
where the epidemic has most severely affected populations, there 
is evidence that accumulating escape mutants in some of the 
critical epitopes for immune control is associated with dimin-
ished protection afforded by the restricting HLA alleles. However, 
although HLA alleles, such as HLA-B*57, may be losing its pro-
tective impact, nonetheless, the legacy to the population of the 
accumulating HLA-B*57-driven mutants is of a gradual lowering 
of the population-level viral fitness. As ART coverage increases 
dramatically in these parts of the world where the epidemic is 
most highly concentrated, so it is likely that the proportion of 
transmissions that arise in acute infection may increase. If this 
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is the case, it is possible that HLA may have less of a role than 
hitherto. However, the goal of reaching all HIV-infected individu-
als with ART, and maintaining viral suppression in those treated 
individuals, is an extraordinary challenge, and it remains to be 
seen what impact HLA will have on HIV evolution in the future.
AUTHOR CONTRiBUTiONS
HK contributed to the manuscript writing. AL contributed with 
ideas, editorial inputs, and critical reviewing of the draft. PG 
wrote the majority of the manuscript and outlined the review 
topic.
ACKNOwLeDGMeNTS
HK is a Sapere Aude awardee from the Danish Research 
Council #12-132295 and #12-134790 and supported by the 
Lundbeck Foundation #R151-2013-14624 and MAERSK 
foundation. PG is a Wellcome Trust Investigator (Grant 
WT104748MA).
ReFeReNCeS
1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. 
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step 
study): a double-blind, randomised, placebo-controlled, test-of-concept trial. 
Lancet (2008) 372:1881–93. doi:10.1016/S0140-6736(08)61591-3 
2. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: 
two phase IIb test-of-concept studies investigating the efficacy of MRK 
adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 
(2010) 5:357–61. doi:10.1097/COH.0b013e32833d2d2b 
3. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, 
et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based 
HIV-1 vaccine in South Africa: a double-blind, randomised, placebo- 
controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 11:507–15. 
doi:10.1016/S1473-3099(11)70098-6 
4. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. 
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: 
unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. 
Lancet Infect Dis (2014) 14:388–96. doi:10.1016/S1473-3099(14)70020-9 
5. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond 
DD, et al. Effector memory T cell responses are associated with protection 
of rhesus monkeys from mucosal simian immunodeficiency virus challenge. 
Nat Med (2009) 15:293–9. doi:10.1038/nm.1935 
6. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, 
et al. Profound early control of highly pathogenic SIV by an effector memory 
T-cell vaccine. Nature (2011) 473:523–7. doi:10.1038/nature10003 
7. Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, 
et al. Immune clearance of highly pathogenic SIV infection. Nature (2013) 
502:100–4. doi:10.1038/nature12519 
8. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et  al. 
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. 
Science (2013) 340:1237874. doi:10.1126/science.1237874 
9. Deeks SG. HIV: shock and kill. Nature (2012) 487:439–40. doi:10.1038/487439a 
10. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, et al. Broad 
CTL response is required to clear latent HIV-1 due to dominance of escape 
mutations. Nature (2015) 517:381–5. doi:10.1038/nature14053 
11. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, 
Ogunlesi AO, et  al. Human immunodeficiency virus genetic variation 
that can escape cytotoxic T cell recognition. Nature (1991) 354:453–9. 
doi:10.1038/354453a0 
12. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, et  al. 
Influence of combinations of human major histocompatibility complex genes 
on the course of HIV-1 infection. Nat Med (1996) 2:405–11. doi:10.1038/
nm0496-405 
13. Goulder PJ, Phillips RE, Colbert RA, Mcadam S, Ogg G, Nowak MA, et al. 
Late escape from an immunodominant cytotoxic T-lymphocyte response 
associated with progression to AIDS. Nat Med (1997) 3:212–7. doi:10.1038/
nm0297-212 
14. O’Brien SJ, Gao X, Carrington M. HLA and AIDS: a cautionary tale. Trends 
Mol Med (2001) 7:379–81. doi:10.1016/S1471-4914(01)02131-1 
15. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A 
whole-genome association study of major determinants for host control of 
HIV-1. Science (2007) 317:944–7. doi:10.1126/science.1143767 
16. Pereyra F, Jia X, Mclaren PJ, Telenti A, De Bakker PI, Walker BD, et al. The 
major genetic determinants of HIV-1 control affect HLA class I peptide 
presentation. Science (2010) 330:1551–7. doi:10.1126/science.1195271 
17. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification 
of self peptides bound to purified HLA-B27. Nature (1991) 353:326–9. 
doi:10.1038/353326a0 
18. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three- dimensional 
structure of HLA-B27 at 2.1 A resolution suggests a general mech-
anism for tight peptide binding to MHC. Cell (1992) 70:1035–48. 
doi:10.1016/0092-8674(92)90252-8 
19. Rotzschke O, Falk K, Stevanovic S, Gnau V, Jung G, Rammensee HG. 
Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and 
B*2705 peptide motifs. Immunogenetics (1994) 39:74–7. doi:10.1007/
BF00171803 
20. Marsh SGE, Parham P, Barber LD. The HLA Facts Book. London: Academic 
Press (2000).
21. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, Mcmichael AJ. 
HIV-1 gag-specific cytotoxic T lymphocytes defined with recombi-
nant vaccinia virus and synthetic peptides. Nature (1988) 336:484–7. 
doi:10.1038/336484a0 
22. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, et  al. 
Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-
B*2705-restricted CD8+ T cells. J Virol (2010) 84:10543–57. doi:10.1128/
JVI.00793-10 
23. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, et  al. 
Clustered mutations in HIV-1 gag are consistently required for escape from 
HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 
193:375–86. doi:10.1084/jem.193.3.375 
24. O’Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, et al. Adenovirus-
specific immunity after immunization with an Ad5 HIV-1 vaccine candidate 
in humans. Nat Med (2009) 15:873–5. doi:10.1038/nm.1991 
25. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, et  al. 
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired 
in cytolytic function. J Exp Med (2000) 192:63–75. doi:10.1084/jem.192.1.63 
26. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, et al. 
Superior control of HIV-1 replication by CD8+ T cells is reflected by their 
avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 204:2473–85. 
doi:10.1084/jem.20070784 
27. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, Moris A, et al. Antigen 
sensitivity is a major determinant of CD8+ T-cell polyfunctionality 
and HIV-suppressive activity. Blood (2009) 113:6351–60. doi:10.1182/
blood-2009-02-206557 
28. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, Hartman KL, 
et al. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-
restricted Gag-derived epitopes associated with relative HIV control. J Virol 
(2011) 85:9334–45. doi:10.1128/JVI.00460-11 
29. Iglesias MC, Almeida JR, Fastenackels S, Van Bockel DJ, Hashimoto M, 
Venturi V, et al. Escape from highly effective public CD8+ T-cell clonotypes 
by HIV. Blood (2011) 118:2138–49. doi:10.1182/blood-2011-01-328781 
30. Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, Mclaren JE, Gras S, 
et  al. A molecular basis for the control of preimmune escape variants by 
HIV-specific CD8+ T cells. Immunity (2013) 38:425–36. doi:10.1016/j.
immuni.2012.11.021 
January 2016 | Volume 6 | Article 66513
Kløverpris et al. HLA and HIV Infection
Frontiers in Immunology | www.frontiersin.org
31. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, et al. 
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte 
response in Gag is associated with a dramatic reduction in human immuno-
deficiency virus type 1 replication. J Virol (2007) 81:12382–93. doi:10.1128/
JVI.01543-07 
32. Schneidewind A, Brockman MA, Sidney J, Wang YE, Chen H, Suscovich 
TJ, et  al. Structural and functional constraints limit options for cytotoxic 
T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope 
in human immunodeficiency virus type 1 capsid. J Virol (2008) 82:5594–605. 
doi:10.1128/JVI.02356-07 
33. Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, et  al. TCR 
clonotypes modulate the protective effect of HLA class I molecules in HIV-1 
infection. Nat Immunol (2012) 13:691–700. doi:10.1038/ni.2342 
34. Shasha D, Walker BD. Lessons to be learned from natural control of 
HIV  –  future directions, therapeutic, and preventive implications. Front 
Immunol (2013) 4:162. doi:10.3389/fimmu.2013.00162 
35. Goulder PJ, Bunce M, Krausa P, Mcintyre K, Crowley S, Morgan B, et  al. 
Novel, cross-restricted, conserved, and immunodominant cytotoxic T lym-
phocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum 
Retroviruses (1996) 12:1691–8. doi:10.1089/aid.1996.12.1691 
36. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, 
Martino L, et al. HLA B*5701 is highly associated with restriction of virus 
replication in a subgroup of HIV-infected long term nonprogressors. Proc 
Natl Acad Sci U S A (2000) 97:2709–14. doi:10.1073/pnas.050567397 
37. Carrington M, O’Brien SJ. The influence of HLA genotype on AIDS. Annu 
Rev Med (2003) 54:535–51. doi:10.1146/annurev.med.54.101601.152346 
38. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, 
et al. Dominant influence of HLA-B in mediating the potential co-evolution 
of HIV and HLA. Nature (2004) 432:769–75. doi:10.1038/nature03113 
39. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, et  al. 
Common genetic variation and the control of HIV-1 in humans. PLoS Genet 
(2009) 5:e1000791. doi:10.1371/journal.pgen.1000791 
40. Thomas R, Apps R, Qi Y, Gao X, Male V, O’Huigin C, et al. HLA-C cell surface 
expression and control of HIV/AIDS correlate with a variant upstream of 
HLA-C. Nat Genet (2009) 41:1290–4. doi:10.1038/ng.486 
41. Kloverpris HN, Stryhn A, Harndahl M, Van Der Stok M, Payne RP, Matthews 
PC, et al. HLA-B*57 micropolymorphism shapes HLA allele-specific epitope 
immunogenicity, selection pressure, and HIV immune control. J Virol (2012) 
86:919–29. doi:10.1128/JVI.06150-11 
42. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV 
evolution: CTL escape mutation and reversion after transmission. Nat Med 
(2004) 10:282–9. doi:10.1038/nm992 
43. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, et  al. 
Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive 
individuals and their transmission recipients. J Exp Med (2009) 206:909–21. 
doi:10.1084/jem.20081984 
44. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, Walker BD, et  al. 
Widespread impact of HLA restriction on immune control and escape 
pathways of HIV-1. J Virol (2012) 86:5230–43. doi:10.1128/JVI.06728-11 
45. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, et al. 
Fitness cost of escape mutations in p24 Gag in association with control 
of human immunodeficiency virus type 1. J Virol (2006) 80:3617–23. 
doi:10.1128/JVI.80.7.3617-3623.2006 
46. Brackenridge S, Evans EJ, Toebes M, Goonetilleke N, Liu MK, Di Gleria K, 
et al. An early HIV mutation within an HLA-B*57-restricted T cell epitope 
abrogates binding to the killer inhibitory receptor 3DL1. J Virol (2011) 
85:5415–22. doi:10.1128/JVI.00238-11 
47. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et  al. 
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 
458:641–5. doi:10.1038/nature07746 
48. Boutwell CL, Rowley CF, Essex M. Reduced viral replication capacity of 
human immunodeficiency virus type 1 subtype C caused by cytotoxic-T- 
lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol 
(2009) 83:2460–8. doi:10.1128/JVI.01970-08 
49. Boutwell CL, Carlson JM, Lin TH, Seese A, Power KA, Peng J, et al. Frequent 
and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the 
human immunodeficiency virus type 1 subtype B Gag proteins. J Virol (2013) 
87:3952–65. doi:10.1128/JVI.03233-12 
50. Miura T, Brumme CJ, Brockman MA, Brumme ZL, Pereyra F, Block BL, 
et al. HLA-associated viral mutations are common in human immunodefi-
ciency virus type 1 elite controllers. J Virol (2009) 83:3407–12. doi:10.1128/
JVI.02459-08 
51. Troyer RM, Mcnevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, et al. Variable 
fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) 
response. PLoS Pathog (2009) 5:e1000365. doi:10.1371/journal.ppat.1000365 
52. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley 
E, et  al. CD8+ T-cell responses to different HIV proteins have discordant 
associations with viral load. Nat Med (2007) 13:46–53. doi:10.1038/nm1520 
53. Santiago ML, Rodenburg CM, Kamenya S, Bibollet-Ruche F, Gao F, Bailes 
E, et al. SIVcpz in wild chimpanzees. Science (2002) 295:465. doi:10.1126/
science.295.5554.465 
54. Wroblewski EE, Norman PJ, Guethlein LA, Rudicell RS, Ramirez MA, Li 
Y, et al. Signature patterns of MHC diversity in three Gombe communities 
of wild chimpanzees reflect fitness in reproduction and immune defense 
against SIVcpz. PLoS Biol (2015) 13:e1002144. doi:10.1371/journal.
pbio.1002144 
55. Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung’u T, et al. 
Additive contribution of HLA class I alleles in the immune control of HIV-1 
infection. J Virol (2010) 84:9879–88. doi:10.1128/JVI.00320-10 
56. Prentice HA, Porter TR, Price MA, Cormier E, He D, Farmer PK, et al. HLA-
B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race? J 
Virol (2013) 87:4043–51. doi:10.1128/JVI.03302-12 
57. Goulder PJ, Brander C, Annamalai K, Mngqundaniso N, Govender U, Tang 
Y, et al. Differential narrow focusing of immunodominant human immuno-
deficiency virus gag-specific cytotoxic T-lymphocyte responses in infected 
African and Caucasoid adults and children. J Virol (2000) 74:5679–90. 
doi:10.1128/JVI.74.12.5679-5690.2000 
58. Huang KH, Goedhals D, Carlson JM, Brockman MA, Mishra S, Brumme ZL, 
et al. Progression to AIDS in South Africa is associated with both reverting 
and compensatory viral mutations. PLoS One (2011) 6:e19018. doi:10.1371/
journal.pone.0019018 
59. Kloverpris HN, Cole DK, Fuller A, Carlson J, Beck K, Schauenburg AJ, 
et  al. A molecular switch in immunodominant HIV-1-specific CD8 T-cell 
epitopes shapes differential HLA-restricted escape. Retrovirology (2015) 
12:20. doi:10.1186/s12977-015-0149-5 
60. Wright JK, Naidoo VL, Brumme ZL, Prince JL, Claiborne DT, Goulder 
PJ, et al. Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral 
replication capacity. J Virol (2012) 86:3193–9. doi:10.1128/JVI.06682-11 
61. Kloverpris HN, Mcgregor R, Mclaren JE, Ladell K, Harndahl M, Stryhn A, 
et al. CD8+ TCR bias and immunodominance in HIV-1 infection. J Immunol 
(2015) 194:5329–45. doi:10.4049/jimmunol.1400854 
62. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, Day C, et al. Differential 
selection pressure exerted on HIV by CTL targeting identical epitopes but 
restricted by distinct HLA alleles from the same HLA supertype. J Immunol 
(2006) 177:4699–708. doi:10.4049/jimmunol.177.12.8878-a 
63. Geldmacher C, Metzler IS, Tovanabutra S, Asher TE, Gostick E, Ambrozak 
DR, et  al. Minor viral and host genetic polymorphisms can dramatically 
impact the biologic outcome of an epitope-specific CD8 T-cell response. 
Blood (2009) 114:1553–62. doi:10.1182/blood-2009-02-206193 
64. Kloverpris HN, Harndahl M, Leslie AJ, Carlson JM, Ismail N, Van Der Stok 
M, et al. HIV control through a single nucleotide on the HLA-B locus. J Virol 
(2012) 86:11493–500. doi:10.1128/JVI.01020-12 
65. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic 
interaction between KIR3DS1 and HLA-B delays the progression to AIDS. 
Nat Genet (2002) 31:429–34. doi:10.1038/ng934 
66. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect 
of a single amino acid change in MHC class I molecules on the rate of 
progression to AIDS. N Engl J Med (2001) 344:1668–75. doi:10.1056/
NEJM200105313442203 
67. Jin X, Gao X, Ramanathan M Jr, Deschenes GR, Nelson GW, O’Brien 
SJ, et  al. Human immunodeficiency virus type 1 (HIV-1)-specific 
CD8+-T-cell responses for groups of HIV-1-infected individuals with 
different HLA-B*35 genotypes. J Virol (2002) 76:12603–10. doi:10.1128/
JVI.76.24.12603-12610.2002 
68. Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, 
et al. Central role of reverting mutations in HLA associations with human 
January 2016 | Volume 6 | Article 66514
Kløverpris et al. HLA and HIV Infection
Frontiers in Immunology | www.frontiersin.org
immunodeficiency virus set point. J Virol (2008) 82:8548–59. doi:10.1128/
JVI.00580-08 
69. Ngumbela KC, Day CL, Mncube Z, Nair K, Ramduth D, Thobakgale C, 
et al. Targeting of a CD8 T cell env epitope presented by HLA-B*5802 is 
associated with markers of HIV disease progression and lack of selection 
pressure. AIDS Res Hum Retroviruses (2008) 24:72–82. doi:10.1089/
aid.2007.0124 
70. Pereyra F, Heckerman D, Carlson JM, Kadie C, Soghoian DZ, Karel D, et al. 
HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes. 
J Virol (2014) 88:12937–48. doi:10.1128/JVI.01004-14 
71. Apps R, Meng Z, Del Prete GQ, Lifson JD, Zhou M, Carrington M. 
Relative expression levels of the HLA class-I proteins in normal and 
HIV-infected cells. J Immunol (2015) 194:3594–600. doi:10.4049/
jimmunol.1403234 
72. Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, et  al. Influence 
of HLA-C expression level on HIV control. Science (2013) 340:87–91. 
doi:10.1126/science.1232685 
73. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, et al. Differential microRNA 
regulation of HLA-C expression and its association with HIV control. Nature 
(2011) 472:495–8. doi:10.1038/nature09914 
74. Kulkarni S, Qi Y, O’Huigin C, Pereyra F, Ramsuran V, Mclaren P, et  al. 
Genetic interplay between HLA-C and MIR148A in HIV control and 
Crohn disease. Proc Natl Acad Sci U S A (2013) 110:20705–10. doi:10.1073/
pnas.1312237110 
75. Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, et al. 
Correlates of protective cellular immunity revealed by analysis of popula-
tion-level immune escape pathways in HIV-1. J Virol (2012) 86:13202–16. 
doi:10.1128/JVI.01998-12 
76. Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince 
J, et  al. HIV transmission. Selection bias at the heterosexual HIV-1 
transmission bottleneck. Science (2014) 345:1254031. doi:10.1126/
science.1254031 
77. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence 
of HIV-1 adaptation to HLA-restricted immune responses at a population 
level. Science (2002) 296:1439–43. doi:10.1126/science.1069660 
78. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM, 
et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011) 
476:96–100. doi:10.1038/nature10237 
79. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, et al. 
Evolution and transmission of stable CTL escape mutations in HIV infection. 
Nature (2001) 412:334–8. doi:10.1038/35085576 
80. Thobakgale CF, Prendergast A, Crawford H, Mkhwanazi N, Ramduth D, 
Reddy S, et al. Impact of HLA in mother and child on disease progression 
of pediatric human immunodeficiency virus type 1 infection. J Virol (2009) 
83:10234–44. doi:10.1128/JVI.00921-09 
81. Adland E, Paioni P, Thobakgale C, Laker L, Mori L, Muenchhoff M, et al. 
Discordant impact of HLA on viral replicative capacity and disease progres-
sion in pediatric and adult HIV infection. PLoS Pathog (2015) 11:e1004954. 
doi:10.1371/journal.ppat.1004954 
82. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, Carlson JM, 
et  al. Transmission of HIV-1 Gag immune escape mutations is associated 
with reduced viral load in linked recipients. J Exp Med (2008) 205:1009–17. 
doi:10.1084/jem.20072457 
83. Boeras DI, Hraber PT, Hurlston M, Evans-Strickfaden T, Bhattacharya T, 
Giorgi EE, et al. Role of donor genital tract HIV-1 diversity in the transmis-
sion bottleneck. Proc Natl Acad Sci U S A (2011) 108:E1156–63. doi:10.1073/
pnas.1103764108 
84. Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, et al. Role 
of transmitted Gag CTL polymorphisms in defining replicative capacity and 
early HIV-1 pathogenesis. PLoS Pathog (2012) 8:e1003041. doi:10.1371/
journal.ppat.1003041 
85. Yue L, Pfafferott KJ, Baalwa J, Conrod K, Dong CC, Chui C, et al. Transmitted 
virus fitness and host T cell responses collectively define divergent infection 
outcomes in two HIV-1 recipients. PLoS Pathog (2015) 11:e1004565. 
doi:10.1371/journal.ppat.1004565 
86. Mphatswe W, Blanckenberg N, Tudor-Williams G, Prendergast A, Thobakgale 
C, Mkhwanazi N, et al. High frequency of rapid immunological progression 
in African infants infected in the era of perinatal HIV prophylaxis. AIDS 
(2007) 21:1253–61. doi:10.1097/QAD.0b013e3281a3bec2 
87. Mori M, Adland E, Paioni P, Swordy A, Mori L, Laker L, et al. Sex differences 
in antiretroviral therapy initiation in pediatric HIV infection. PLoS One 
(2015) 10:e0131591. doi:10.1371/journal.pone.0131591 
88. Muenchhoff M, Prendergast AJ, Goulder PJ. Immunity to HIV in early life. 
Front Immunol (2014) 5:391. doi:10.3389/fimmu.2014.00391 
89. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, Mcintosh K, Karthas N, et al. 
Immune escape precedes breakthrough human immunodeficiency virus 
type 1 viremia and broadening of the cytotoxic T-lymphocyte response 
in an HLA-B27-positive long-term-nonprogressing child. J Virol (2004) 
78:8927–30. doi:10.1128/JVI.78.16.8927-8930.2004 
90. Liu D, Zuo T, Hora B, Song H, Kong W, Yu X, et al. Preexisting compensatory 
amino acids compromise fitness costs of a HIV-1 T cell escape mutation. 
Retrovirology (2014) 11:101. doi:10.1186/s12977-014-0101-0 
91. Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, Trocha A, et al. 
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL 
response. J Immunol (2005) 174:7524–30. doi:10.4049/jimmunol.174.12.7524 
92. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, Cullen C, et al. 
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 
(2004) 10:275–81. doi:10.1038/nm998 
93. Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, 
et al. Transmission and accumulation of CTL escape variants drive negative 
associations between HIV polymorphisms and HLA. J Exp Med (2005) 
201:891–902. doi:10.1084/jem.20041455 
94. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, Kadie C, et al. 
Founder effects in the assessment of HIV polymorphisms and HLA allele 
associations. Science (2007) 315:1583–6. doi:10.1126/science.1131528 
95. Matthews PC, Koyanagi M, Kloverpris HN, Harndahl M, Stryhn A, Akahoshi 
T, et  al. Differential clade-specific HLA-B*3501 association with HIV-1 
disease outcome is linked to immunogenicity of a single Gag epitope. J Virol 
(2012) 86:12643–54. doi:10.1128/JVI.01381-12 
96. Payne R, Muenchhoff M, Mann J, Roberts HE, Matthews P, Adland E, et al. 
Impact of HLA-driven HIV adaptation on virulence in populations of 
high HIV seroprevalence. Proc Natl Acad Sci U S A (2014) 111:E5393–400. 
doi:10.1073/pnas.1413339111 
97. Fryer HR, Frater J, Duda A, Roberts MG, Investigators ST, Phillips RE, et al. 
Modelling the evolution and spread of HIV immune escape mutants. PLoS 
Pathog (2010) 6:e1001196. doi:10.1371/journal.ppat.1001196 
98. Cotton LA, Kuang XT, Le AQ, Carlson JM, Chan B, Chopera DR, et  al. 
Genotypic and functional impact of HIV-1 adaptation to its host population 
during the North American epidemic. PLoS Genet (2014) 10:e1004295. 
doi:10.1371/journal.pgen.1004295 
99. Loffredo JT, Burwitz BJ, Rakasz EG, Spencer SP, Stephany JJ, Vela JP, et al. The 
antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is 
unrelated to epitope specificity and is abrogated by viral escape. J Virol (2007) 
81:2624–34. doi:10.1128/JVI.01912-06 
100. Adland E, Carlson JM, Paioni P, Kloverpris H, Shapiro R, Ogwu A, et  al. 
Nef-specific CD8+ T cell responses contribute to HIV-1 immune control. 
PLoS One (2013) 8:e73117. doi:10.1371/journal.pone.0073117 
101. Valentine LE, Loffredo JT, Bean AT, Leon EJ, Macnair CE, Beal DR, et al. 
Infection with “escaped” virus variants impairs control of simian immuno-
deficiency virus SIVmac239 replication in Mamu-B*08-positive macaques. J 
Virol (2009) 83:11514–27. doi:10.1128/JVI.01298-09 
102. Kloverpris HN, Adland E, Koyanagi M, Stryhn A, Harndahl M, Matthews PC, 
et al. HIV subtype influences HLA-B*07:02-associated HIV disease outcome. 
AIDS Res Hum Retroviruses (2014) 30:468–75. doi:10.1089/AID.2013.0197 
103. Kawashima Y, Kuse N, Gatanaga H, Naruto T, Fujiwara M, Dohki S, et al. 
Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele 
HLA-B*5101. J Virol (2010) 84:7151–60. doi:10.1128/JVI.00171-10 
104. Herbeck JT, Muller V, Maust BS, Ledergerber B, Torti C, Di Giambenedetto 
S, et al. Is the virulence of HIV changing? A meta-analysis of trends in prog-
nostic markers of HIV disease progression and transmission. AIDS (2012) 
26:193–205. doi:10.1097/QAD.0b013e32834db418 
105. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. 
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. 
Science (1996) 272:1167–70. doi:10.1126/science.272.5265.1167 
106. Seage GR III, Holte S, Gross M, Koblin B, Marmor M, Mayer KH, 
et  al. Case-crossover study of partner and situational factors for 
unprotected sex. J Acquir Immune Defic Syndr (2002) 31:432–9. 
doi:10.1097/00126334-200212010-00010 
January 2016 | Volume 6 | Article 66515
Kløverpris et al. HLA and HIV Infection
Frontiers in Immunology | www.frontiersin.org
107. Group I-ES, Committee SS, Abrams D, Levy Y, Losso MH, Babiker A, et al. 
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 
361:1548–59. doi:10.1056/NEJMoa0903175 
108. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. 
Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prog-
nostic value of low CD4+ T cell levels: results of 6 years of follow-up. The 
Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic 
Syndr (1993) 6:904–12. 
109. Silvestri G, Sodora DL, Koup RA, Paiardini M, O’Neil SP, Mcclure HM, et al. 
Nonpathogenic SIV infection of sooty mangabeys is characterized by limited 
bystander immunopathology despite chronic high-level viremia. Immunity 
(2003) 18:441–52. doi:10.1016/S1074-7613(03)00060-8 
110. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, et  al. 
Nonpathogenic SIV infection of African green monkeys induces a strong 
but rapidly controlled type I IFN response. J Clin Invest (2009) 119:3544–55. 
doi:10.1172/JCI40093 
111. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB, et  al. 
Immune activation set point during early HIV infection predicts subsequent 
CD4+ T-cell changes independent of viral load. Blood (2004) 104:942–7. 
doi:10.1182/blood-2003-09-3333 
112. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, 
et  al. Gut epithelial barrier dysfunction and innate immune activation 
predict mortality in treated HIV infection. J Infect Dis (2014) 210:1228–38. 
doi:10.1093/infdis/jiu238 
113. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, et  al. Global 
genomic analysis reveals rapid control of a robust innate response in SIV-
infected sooty mangabeys. J Clin Invest (2009) 119:3556–72. doi:10.1172/
JCI40115 
114. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. 
Immunity (2012) 37:426–40. doi:10.1016/j.immuni.2012.09.005 
115. Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, et  al. 
Replicative fitness of transmitted HIV-1 drives acute immune activation, 
proviral load in memory CD4+ T cells, and disease progression. Proc Natl 
Acad Sci U S A (2015) 112:E1480–9. doi:10.1073/pnas.1421607112 
116. Paiardini M, Cervasi B, Reyes-Aviles E, Micci L, Ortiz AM, Chahroudi 
A, et  al. Low levels of SIV infection in sooty mangabey central memory 
CD(4)(+) T cells are associated with limited CCR5 expression. Nat Med 
(2011) 17:830–6. doi:10.1038/nm.2395 
117. Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, et al. 
HIV RNA level in early infection is predicted by viral load in the transmission 
source. AIDS (2010) 24:941–5. doi:10.1097/QAD.0b013e328337b12e 
118. Brander C, Walker BD. Gradual adaptation of HIV to human host popu-
lations: good or bad news? Nat Med (2003) 9:1359–62. doi:10.1038/nm941 
119. Campbell TB, Schneider K, Wrin T, Petropoulos CJ, Connick E. Relationship 
between in  vitro human immunodeficiency virus type 1 replication 
rate and virus load in plasma. J Virol (2003) 77:12105–12. doi:10.1128/
JVI.77.22.12105-12112.2003 
120. Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, Rosato PC, et al. 
Early selection in Gag by protective HLA alleles contributes to reduced 
HIV-1 replication capacity that may be largely compensated for in chronic 
infection. J Virol (2010) 84:11937–49. doi:10.1128/JVI.01086-10 
121. Brumme ZL, Li C, Miura T, Sela J, Rosato PC, Brumme CJ, et al. Reduced 
replication capacity of NL4-3 recombinant viruses encoding reverse tran-
scriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune 
Defic Syndr (2011) 56:100–8. doi:10.1097/QAI.0b013e3181fe9450 
122. Nomura S, Hosoya N, Brumme ZL, Brockman MA, Kikuchi T, Koga M, 
et  al. Significant reductions in Gag-protease-mediated HIV-1 replication 
capacity during the course of the epidemic in Japan. J Virol (2013) 87:1465–76. 
doi:10.1128/JVI.02122-12 
123. Juarez-Molina CI, Payne R, Soto-Nava M, Avila-Rios S, Valenzuela-Ponce 
H, Adland E, et  al. Impact of HLA selection pressure on HIV fitness at a 
population level in Mexico and Barbados. J Virol (2014) 88:10392–8. 
doi:10.1128/JVI.01162-14 
124. Fraser C, Hollingsworth TD, Chapman R, De Wolf F, Hanage WP. Variation 
in HIV-1 set-point viral load: epidemiological analysis and an evolutionary 
hypothesis. Proc Natl Acad Sci U S A (2007) 104:17441–6. doi:10.1073/
pnas.0708559104 
125. Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, et al. 
Temporal trends in prognostic markers of HIV-1 virulence and transmissibil-
ity: an observational cohort study. Lancet HIV (2014) 3:119–26. doi:10.1016/
S2352-3018(14)00002-2 
126. Adland E, Klenerman P, Goulder P, Matthews PC. Ongoing burden of disease 
and mortality from HIV/CMV coinfection in Africa in the antiretroviral 
therapy era. Front Microbiol (2015) 6:1016. doi:10.3389/fmicb.2015.01016
127. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, et al. 
Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 
(1999) 397:436–41. doi:10.1038/17130 
128. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, 
Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act 
in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. 
Lancet (2001) 357:1149–53. doi:10.1016/S0140-6736(00)04331-2 
129. Wawer MJ, Reynolds SJ, Serwadda D, Kigozi G, Kiwanuka N, Gray RH. Might 
male circumcision be more protective against HIV in the highly exposed? 
An immunological hypothesis. AIDS (2005) 19:2181–2. doi:10.1097/01.
aids.0000194132.51006.4f 
130. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual 
infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 
(2008) 8:553–63. doi:10.1016/S1473-3099(08)70156-7 
131. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal 
intercourse: systematic review, meta-analysis and implications for HIV 
prevention. Int J Epidemiol (2010) 39:1048–63. doi:10.1093/ije/dyq057 
132. Goodreau SM, Cassels S, Kasprzyk D, Montano DE, Greek A, Morris M. 
Concurrent partnerships, acute infection and HIV epidemic dynamics among 
young adults in Zimbabwe. AIDS Behav (2012) 16:312–22. doi:10.1007/
s10461-010-9858-x 
133. Dennis AM, Herbeck JT, Brown AL, Kellam P, De Oliveira T, Pillay D, et al. 
Phylogenetic studies of transmission dynamics in generalized HIV epidem-
ics: an essential tool where the burden is greatest? J Acquir Immune Defic 
Syndr (2014) 67:181–95. doi:10.1097/QAI.0000000000000271 
134. Hollingsworth TD, Pilcher CD, Hecht FM, Deeks SG, Fraser C. High 
transmissibility during early HIV infection among men who have sex with 
men-San Francisco, California. J Infect Dis (2015) 211:1757–60. doi:10.1093/
infdis/jiu831 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Kløverpris, Leslie and Goulder. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
